AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback